Neurobiological and Psychological Maintenance Mechanisms Associated With Anticipatory Reward in Bulimia Nervosa

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-55
SponsorUniversity of Minnesota

About this trial

The purpose of this investigation is to identify the potentially crucial role of anticipatory reward mechanisms maintaining bulimic behavior (i.e., binge eating and purging) in bulimia nervosa (BN). The research will investigate neural and psychological anticipatory processes in BN, both in the scanner and the natural environment.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Right-handed

Ability to read and speak in English

Eating Disorder Examination (EDE) diagnosis of BN (i.e., at least one objective bulimic episode and one self-induced vomiting episode per week for at three months) with binge episodes always accompanied by self-induced vomiting

Stable dose for at least 6 weeks of any recent changes in medication impacting mood, appetite, or weight

Disqualifiers

History of gastric bypass surgery

Medical condition acutely affecting eating behavior and/or weight (i.e., pregnancy, lactation, thyroid disease)

Current medical or psychiatric instability (i.e., hospitalization required in the past three months)

Lifetime history of psychosis or bipolar disorder

Trial population

Adults with or without bulimia nervosa

Trial design

Design model

Case-control

Time perspective

Retrospective

Treatments tested in this trial

Not listed

Trial groups

100 Participants
are grouped into 2 trial groups
Group A: Bulimia Nervosa
Group B: Healthy Control

Trial outcomes

Primary outcomes

1

The Positive and Negative Affect Schedule (PANAS) self-reported negative affect

The Positive and Negative Affect Schedule (PANAS) is a self-report measure comprising two scales, one of which we will use to assess participants' negative affect. The scale includes ten Likert-style items, which participants rate from 1 = not at all to 5 = very much. Composite scores range from 10-50, and a score of 50 indicates greater negative affect. The PANAS will be administered to measure emotion at multiple times during the second visit as well as during EMA administration and to establish a baseline at the first visit.

Time frame
1-2 months
2

The Positive and Negative Affect Schedule (PANAS) self-reported positive affect

The Positive and Negative Affect Schedule (PANAS) is a self-report measure comprising two scales, one of which we will use to assess participants' positive affect. The scale includes ten Likert-style items, which participants rate from 1 = not at all to 5 = very much. Composite scores range from 10-50, and a score of 50 indicates greater positive affect. The PANAS will be administered to measure emotion at multiple times during the second visit as well as during EMA administration and to establish a baseline at the first visit.

Time frame
1-2 months
3

Activation in regions of the limbic threat network

fMRI will be used to assess the neural correlates of bulimic behavior anticipation. Outcome is reported as the mean z-scores from voxels in limbic regions (amygdala, hippocampus, insula) extracted from a 2x2 analysis of the BED versus HC groups in the food choice versus shopping contrast results of the fMRI task regression analysis.

Time frame
approximately 4 hours
4

Activation in regions of the striatal approach network

fMRI will be used to assess the neural correlates of bulimic behavior anticipation. Outcome is reported as the mean z-scores from voxels in striatal regions (nucleus accumbens, caudate and putamen) extracted from a 2x2 analysis of the BED versus HC groups the food choice versus shopping contrast results of the fMRI task regression analysis.

Time frame
approximately 4 hours

Secondary outcomes

1

Duration of illness

Outcome is reported as the number of days participants in the bulimia nervosa group experience illness.

Time frame
1-2 months

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.